TY - JOUR
T1 - Treatment costs for advanced prostate cancer using luteinizing hormone-releasing hormone agonists: A solid biodegradable leuprorelin implant versus other formulations
AU - Merseburger, Axel S.
AU - Björk, Thomas
AU - Whitehouse, James
AU - Meani, Davide
N1 - Publisher Copyright:
© Davide Meani.
Copyright:
Copyright 2015 Elsevier B.V., All rights reserved.
PY - 2015/9
Y1 - 2015/9
N2 - Aim: To compare treatment costs with alternative luteinizing hormone-releasing hormone (LHRH) agonist preparations and determine whether a leuprorelin solid implant is associated with potential cost savings. Patients & methods: A hypothetical population of 1000 prostate cancer patients was apportioned between the three most commonly-prescribed LHRH agonist preparations. Differentiated annual costs for 1- and 3-monthly formulations were calculated for France, Germany, Italy, Spain, the UK (EU5) and Sweden, and compared with the leuprorelin solid implant. Results: Compared with alternative formulations, leuprorelin solid implants had potential annual cost savings/1000 patients of €353,000 (EU5) and €699,000 (Sweden; 1-month formulations), and €259,000 (EU5) and €300,000 (Sweden; 3-month formulations). Conclusion: The leuprorelin solid implant was associated with potential cost savings compared with the most commonly used LHRH agonist preparations.
AB - Aim: To compare treatment costs with alternative luteinizing hormone-releasing hormone (LHRH) agonist preparations and determine whether a leuprorelin solid implant is associated with potential cost savings. Patients & methods: A hypothetical population of 1000 prostate cancer patients was apportioned between the three most commonly-prescribed LHRH agonist preparations. Differentiated annual costs for 1- and 3-monthly formulations were calculated for France, Germany, Italy, Spain, the UK (EU5) and Sweden, and compared with the leuprorelin solid implant. Results: Compared with alternative formulations, leuprorelin solid implants had potential annual cost savings/1000 patients of €353,000 (EU5) and €699,000 (Sweden; 1-month formulations), and €259,000 (EU5) and €300,000 (Sweden; 3-month formulations). Conclusion: The leuprorelin solid implant was associated with potential cost savings compared with the most commonly used LHRH agonist preparations.
UR - http://www.scopus.com/inward/record.url?scp=84945321592&partnerID=8YFLogxK
U2 - 10.2217/cer.14.82
DO - 10.2217/cer.14.82
M3 - Journal articles
C2 - 25521079
AN - SCOPUS:84945321592
SN - 2042-6305
VL - 4
SP - 447
EP - 453
JO - Journal of Comparative Effectiveness Research
JF - Journal of Comparative Effectiveness Research
IS - 5
ER -
